Blue Bird Stock: Reconsidering Investment Amidst Market Overheating (Hold Rating)
Finance

Blue Bird Stock: Reconsidering Investment Amidst Market Overheating (Hold Rating)

authorBy Morgan Housel
DateJun 17, 2026
Read time2 min

Blue Bird Corporation is demonstrating strong operational momentum, propelled by its recent strategic acquisition of the Micro Bird joint venture and a continually expanding order book. The company has revised its financial outlook upwards for both 2026 and 2030, reflecting confidence in its long-term profitability. This growth trajectory is significantly supported by a prevailing replacement cycle for school buses and the successful penetration into broader commercial markets, underpinned by ongoing expansions in manufacturing capacity.

Despite these encouraging fundamentals, which include an appealing Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization (EV/EBITDA) of 8.4x and a Price-to-Earnings (P/E) ratio of 14.48x, the stock's valuation appears stretched. Its swift market appreciation has left little room for error compared to its estimated long-term price target of $107. The current market conditions suggest overbought signals, and the stock has encountered resistance near the $70 level. These factors, combined with a notable short interest ratio of 10.43%, indicate a probable short-term market correction.

Given the present circumstances, it is recommended to maintain a 'Hold' position on Blue Bird Corporation shares. Prospective investors should consider delaying their entry until the stock approaches a more attractive valuation range, specifically between the 100-day and 200-day moving averages, which are currently identified at $61 and $57, respectively. Such a disciplined approach would provide an enhanced margin of safety, aligning investment decisions with a more favorable risk-reward profile.

More Articles
Finance
GE Aerospace: Strong Fundamentals and Growth Prospects
GE Aerospace continues to be rated as a 'Buy' with a target price of $402.85, indicating a potential upside of nearly 18%. This positive outlook is attributed to the company's leading position in engine programs like CFM LEAP, GEnx, and GE9X, coupled with robust aftermarket revenue streams. Despite recent geopolitical risks and supply chain concerns, GE Aerospace's diversified fleet and pricing power are expected to mitigate these challenges, maintaining its growth trajectory.
By Suze OrmanJun 17, 2026
Finance
Eikon Therapeutics Faces Lock-Up Expiry Risks Despite Promising Clinical Strategy
Eikon Therapeutics has been assigned a Sell rating due to substantial dilution risks associated with its impending lock-up expiry. While its lead asset, EIK1001, demonstrates encouraging early data in NSCLC and melanoma, pivotal trial results are not anticipated until 2027. The company's cash reserves are projected to last only until the second half of 2027, making additional equity financing highly probable within the next year. With insider-held shares set to unlock in August 2026 and a lack of significant near-term catalysts, further stock depreciation is expected.
By Michele FerreroJun 17, 2026
Finance
Market Dynamics and Fund Performance in Q1 2026
The first quarter of 2026 witnessed significant shifts in global markets, driven by geopolitical tensions and their impact on commodity prices. The closure of the Strait of Hormuz disrupted crucial supply chains, leading to a hawkish repricing of interest rate expectations by central banks. Technology sectors experienced contrasting fortunes, with large cap companies exceeding capital expenditure forecasts while software firms faced challenges due to AI disruption. Amidst these changes, the U.S. Treasury yield curve flattened as short-term yields rose more sharply than long-term yields. Northern Funds Limited Term U.S. Government Fund underperformed its benchmark, primarily influenced by management fees and its exposure to U.S. TIPS.
By David RubensteinJun 17, 2026
Finance
Nexstar Media Group: Legal Challenges and Undervalued Potential
Nexstar Media Group (NXST) has seen its stock decline by 27% following legal hurdles and integration delays in its acquisition of TEGNA. Despite these challenges, the company's standalone performance remains strong, with robust Q1 EPS and soaring political advertising revenue. NXST offers a secure 4.3% dividend yield and trades at a nearly 15% free cash flow yield, suggesting significant undervaluation with a fair value estimated between $210 and $300.
By David RubensteinJun 17, 2026
Finance
Lincoln Memorial Reflecting Pool: Hydrogen Peroxide Treatment and Political Controversy
The Lincoln Memorial Reflecting Pool recently underwent hydrogen peroxide treatment to combat an algae bloom, bringing renewed attention to a $13.1 million renovation project. While the National Park Service assures the treatment is safe and effective, several Democratic senators, including Chuck Schumer, have criticized the project as wasteful, particularly a $13.1 million no-bid contract, and questioned former President Trump's priorities.
By Suze OrmanJun 17, 2026